Share：
Share this content in WeChat
X
[Chinese] [PDF] 574 2
• Clinical Article •
The value of MRI histogram analysis in predicting the long-term therapeutic effect after surgery for growth hormone-secreting pituitary neuroendocrine tumors
QU Rui  DONG Wenjie  LIU Jianli 

Cite this article as: QU R, DONG　W J, LIU J L. The value of MRI histogram analysis in predicting the long-term therapeutic effect after surgery for growth hormone-secreting pituitary neuroendocrine tumors[J]. Chin J Magn Reson Imaging, 2025, 16(9): 53-59. DOI:10.12015/issn.1674-8034.2025.09.009.


[Abstract] Objective To explore the value of MRI histogram analysis in predicting the long-term efficacy of transsphenoidal neuroendoscopic surgery for growth hormone-secreting pituitary neuroendocrine tumors before and early after surgery.Materials and Methods A total of 43 patients with growth hormone-secreting pituitary neuroendocrine tumors from June 2021 to June 2023 were retrospectively included, among which 22 achieved remission and 21 did not. Clinical, pathological, and laboratory data were evaluated and recorded. Histogram parameters were extracted and calculated based on the T2WI sequence. The differences in histogram parameters combined with preoperative and early postoperative clinical semantic features between the long-term remission and non-remission groups were analyzed, and their diagnostic performance was evaluated.Results In the preoperative clinical semantic characteristics between the two groups, statistically significant differences were observed in cavernous sinus invasion (χ2 = 5.495), acromegaly (χ2 = 4.240), preoperative growth hormone (GH) levels (Z = -2.821), and serum insulin-like growth factor-1 (IGF-1) levels (t = -2.856) (all P < 0.05). Among the early postoperative clinical semantic features, immediate postoperative GH (Z = -3.681) and IGF-1 levels (t = 0.247) also demonstrated statistically significant differences (both P < 0.05). Regarding histogram parameters, significant differences were found in area (t = -2.716) and kurtosis (Z = -2.332) (both P < 0.05). The diagnostic performance of the model was evaluated using receiver operating characteristic (ROC) curve analysis and area under the curve (AUC). The predictive model incorporating MRI histogram parameters with preoperative and early postoperative clinical, pathological, and laboratory data exhibited optimal performance, achieving an AUC of 0.963. At a cutoff value of 0.447, the sensitivity and specificity were 95.2% and 86.4%, respectively.Conclusions T2WI histogram parameters provide additional value in predicting the long-term efficacy of GH-PitNET postoperative outcomes.
[Keywords] pituitary neuroendocrine tumor；magnetic resonance imaging；histogram analysis；prognosis；efficacy

QU Rui1   DONG Wenjie1, 2   LIU Jianli1*  

1 Department of Radiology, the Second Hospital of Lanzhou University, Lanzhou 730030, China

2 The Second Clinical Medical College of Lanzhou University, Lanzhou 730000, China

Corresponding author: LIU J L, E-mail: liujl_1219@163.com

Conflicts of interest   None.

Received  2025-02-25
Accepted  2025-09-03
DOI: 10.12015/issn.1674-8034.2025.09.009
Cite this article as: QU R, DONG　W J, LIU J L. The value of MRI histogram analysis in predicting the long-term therapeutic effect after surgery for growth hormone-secreting pituitary neuroendocrine tumors[J]. Chin J Magn Reson Imaging, 2025, 16(9): 53-59. DOI:10.12015/issn.1674-8034.2025.09.009.

[1]
ASA S L, METE O, PERRY A, et al. Overview of the 2022 WHO Classification of Pituitary Tumors[J]. Endocr Pathol, 2022, 33(1): 6-26. DOI: 10.1007/s12022-022-09703-7.
[2]
TRITOS N A, MILLER K K. Diagnosis and Management of Pituitary Adenomas: A Review[J]. JAMA, 2023, 329(16): 1386-1398. DOI: 10.1001/jama.2023.5444.
[3]
GADELHA M R, KASUKI L. Refractory somatotroph adenomas[J]. Pituitary, 2023, 26(3): 266-268. DOI: 10.1007/s11102-023-01324-5.
[4]
BURCEA I F, NĂSTASE V N, CÎMPEAN A M, et al. Clinicopathological Features of Growth Hormone-producing Pituitary Adenomas and Correlation With Preoperative Laboratory Findings[J]. Anticancer Res, 2021, 41(5): 2669-2680. DOI: 10.21873/anticanres.15048.
[5]
PETERSENN S, FLESERIU M, CASANUEVA F F, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement[J]. Nat Rev Endocrinol, 2023, 19(12): 722-740. DOI: 10.1038/s41574-023-00886-5.
[6]
ZHAO Z, XIAO D, NIE C, et al. Development of a Nomogram Based on Preoperative Bi-Parametric MRI and Blood Indices for the Differentiation Between Cystic-Solid Pituitary Adenoma and Craniopharyngioma[J/OL]. Front Oncol, 2021, 11: 709321 [2025-02-25]. https://doi.org/10.3389/fonc.2021.709321. DOI: 10.3389/fonc.2021.709321.
[7]
NIU J, ZHANG S, MA S, et al. Preoperative prediction of cavernous sinus invasion by pituitary adenomas using a radiomics method based on magnetic resonance images[J]. Eur Radiol, 2019, 29(3): 1625-1634. DOI: 10.1007/s00330-018-5725-3.
[8]
HAN T, LIU X, SUN J, et al. T2-Weighted Imaging and Apparent Diffusion Coefficient Histogram Parameters Predict Meningioma Consistency[J]. Acad Radiol, 2024, 31(6): 2511-2520. DOI: 10.1016/j.acra.2023.12.014.
[9]
KASUKI L, ANTUNES X, LAMBACK E B, et al. Acromegaly: Update on Management and Long-Term Morbidities[J]. Endocrinol Metab Clin North Am, 2020, 49(3): 475-486. DOI: 10.1016/j.ecl.2020.05.007.
[10]
TAN H W, QIN M, YU Y R, et al. Progress in diagnosis and drug treatment of acromegaly: Interpretation of the 2021 Update of the Pituitary Association Guidelines for Diagnosis and Treatment of Acromegaly[J]. Chin Gen Prac, 2021, 24(27): 3397-3403. DOI: 10.12114/j.issn.1007-9572.2021.02.016.
[11]
Chinese Society of Neurosurgery, Chinese Pituitary Adenoma Collaboration Group, Chinese Society of Endocrinology. Chinese guide of diagnosis and treatment of acromegaly (2013)[J]. Chin J Neurosurg, 2013, 29(10): 975-979. DOI: 10.3760/cma.j.issn.1001-2346.2013.10.003.
[12]
RAHIMLI T, HIDAYETOV T, YUSIFLI Z, et al. Endoscopic Endonasal Approach to Giant Pituitary Adenomas: Surgical Outcomes and Review of the Literature[J/OL]. World Neurosurg, 2021, 149: e1043-e1055 [2025-02-25]. https://doi.org/10.1016/j.wneu.2021.01.019. DOI: 10.1016/j.wneu.2021.01.019.
[13]
SU C Q, ZHANG X, PAN T, et al. Texture Analysis of High b-Value Diffusion-Weighted Imaging for Evaluating Consistency of Pituitary Macroadenomas[J]. J Magn Reson Imaging, 2020, 51(5): 1507-1513. DOI: 10.1002/jmri.26941.
[14]
CHEN J M, WAN Q, ZHU H Y, et al. Value of texture prediction of pituitary macroadenoma based on conventional magnetic resonance imaging model[J]. Natl Med J China, 2020, 100 (45): 3626-3631. DOI: 10.3760/cma.j.cn112137-20200511-01511.
[15]
KNOSP E, STEINER E, KITZ K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings[J]. Neurosurgery, 1993, 33(4): 610-618. DOI: 10.1227/00006123-199310000-00008.
[16]
DAI C, KANG J, LIU X, et al. How to Classify and Define Pituitary Tumors: Recent Advances and Current Controversies[J/OL]. Front Endocrinol (Lausanne), 2021, 12: 604644 [2025-02-25]. https://doi.org/10.3389/fendo.2021.604644. DOI: 10.3389/fendo.2021.604644.
[17]
NISHIOKA H, HARAOKA J, AKADA K, et al. Gender-related differences in prolactin secretion in pituitary prolactinomas[J]. Neuroradiology, 2002, 44(5): 407-410. DOI: 10.1007/s00234-002-0774-2.
[18]
MUNAWAR K, NAYAK G, FATTERPEKAR G M, et al. Cavernous sinus lesions[J]. Clin Imaging, 2020, 68: 71-89. DOI: 10.1016/j.clinimag.2020.06.029.
[19]
ASMARO K, ZHANG M, RODRIGUES A J, et al. Cytodifferentiation of pituitary tumors influences pathogenesis and cavernous sinus invasion[J]. J Neurosurg, 2023, 139(5):1216-1224. DOI: 10.3171/2023.3.JNS221949.
[20]
CHEN Y, CAI F, CAO J, et al. Analysis of Related Factors of Tumor Recurrence or Progression After Transnasal Sphenoidal Surgical Treatment of Large and Giant Pituitary Adenomas and Establish a Nomogram to Predict Tumor Prognosis[J/OL]. Front Endocrinol (Lausanne), 2021, 12: 793337 [2025-02-25]. https://doi.org/10.3389/fendo.2021.793337. DOI: 10.3389/fendo.2021.793337.
[21]
GUO X, ZHANG R, ZHANG D, et al. Determinants of immediate and long-term remission after initial transsphenoidal surgery for acromegaly and outcome patterns during follow-up: a longitudinal study on 659 patients[J]. J Neurosurg, 2022, 137(3): 618-628. DOI: 10.3171/2021.11.JNS212137.
[22]
FLESERIU M, LANGLOIS F, LIM D S T, et al. Acromegaly: pathogenesis, diagnosis, and management[J]. Lancet Diabetes Endocrinol, 2022, 10(11): 804-826. DOI: 10.1016/S2213-8587(22)00244-3.
[23]
ERSHADINIA N, TRITOS N A. Diagnosis and Treatment of Acromegaly: An Update[J]. Mayo Clin Proc, 2022, 97(2): 333-346. DOI: 10.1016/j.mayocp.2021.11.007.
[24]
FERRÉS A, REYES L, DI SOMMA A, et al. The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up[J/OL]. Cancers (Basel), 2022, 15(1): 267 [2025-02-25]. https://doi.org/10.3390/cancers15010267. DOI: 10.3390/cancers15010267.
[25]
KIM E H, OH M C, LEE E J, et al. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly[J]. Neurosurgery, 2012, 70(5): 1106-1113. DOI: 10.1227/NEU.0b013e31823f5c16.
[26]
SHEN M, CHEN Z, SHOU X, et al. 2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly[J/OL]. J Neuroendocrinol, 2021, 33(5): e12958 [2025-02-25]. https://doi.org/10.1111/jne.12958. DOI: 10.1111/jne.12958.
[27]
XIE J, WU Z B. New pathologic classification and clinical implications of pituitary neuroendocrine tumors in the 2022 edition of the World Health Organization[J]. Natl Med J China, 2022, 102 (47): 3723-3726. DOI: 10.3760/cma.j.cn112137-20220417-00825.
[28]
RAVEROT G, ILIE M D, LASOLLE H, et al. Aggressive pituitary tumours and pituitary carcinomas[J]. Nat Rev Endocrinol, 2021, 17(11): 671-684. DOI: 10.1038/s41574-021-00550-w.
[29]
LI P, ZHANG D, MA S, et al. Consistency of pituitary adenomas: Amounts of collagen types I and III and the predictive value of T2WI MRI[J/OL]. Exp Ther Med, 2021, 22(5): 1255 [2025-02-25]. https://doi.org/10.3892/etm.2021.10690. DOI: 10.3892/etm.2021.10690.
[30]
GAO Y, LIU WV, LI L, et al. Usefulness of T2-Weighted Images with Deep-Learning-Based Reconstruction in Nasal Cartilage[J/OL]. Diagnostics (Basel), 2023, 13(19): 3044 [2025-02-25]. https://doi.org/10.3390/diagnostics13193044. DOI: 10.3390/diagnostics13193044.
[31]
YANG L, LIU D, FANG X, et al. Rectal cancer: can T2WI histogram of the primary tumor help predict the existence of lymph node metastasis?[J]. Eur Radiol, 2019, 29(12): 6469-6476. DOI: 10.1007/s00330-019-06328-z.
[32]
CHEN M, DUAN L, MIAO H, et al. Clinical characteristics and therapeutic outcomes of acromegalic patients with giant growth hormone-secreting pituitary adenomas: a single-center study of 67 cases[J]. Pituitary, 2023, 26(6): 675-685. DOI: 10.1007/s11102-023-01356-x.
[33]
WANG Y P, LI Y J, LI B, et al. Correlation analysis of anterior pituitary hormone level and tumor size in different types of pituitary adenomas[J]. Chin J Intern Med, 2023, 62(8): 979-986. DOI: 10.3760/cma.j.cn112138-20221019-00765.
[34]
CAO T, JIANG R, ZHENG L, et al. T1 and ADC histogram parameters may be an in vivo biomarker for predicting the grade, subtype, and proliferative activity of meningioma[J]. Eur Radiol, 2023, 33(1): 258-269. DOI: 10.1007/s00330-022-09026-5.
[35]
PALMUCCI S, TIRALONGO F, GALIOTO F, et al. Histogram-based analysis in progressive pulmonary fibrosis: relationships between pulmonary functional tests and HRCT indexes[J/OL]. Br J Radiol, 2023, 96(1151): 20221160 [2025-02-25]. https://doi.org/10.1259/bjr.20221160. DOI: 10.1259/bjr.20221160.

PREV Prediction of lower-grade glioma IDH-1 mutation status using a combined model of radiomics and transformer deep learning features based on multi-parametric MRI of intratumoral and peritumoral edema
NEXT Application value of deep learning-based accelerated T1WI and T2WI sequences in head and neck tumors
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn